Drugs / INP20
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04163562 | Mar 2020 → May 2025 overdue | food allergy | InnoUp Farma S.L. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INP20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04163562 ↗ |
| Modality | Protein / enzyme biologic | “two doses of peanut protein selected from Part A” NCT04163562 ↗ |
| Route | Oral | “Part A: Oral INP20 administration at ascending doses once daily for 2 weeks” NCT04163562 ↗ |